Cytokinetics, Inc. shared positive results from the Phase 1 study of CK-4021586 at a medical conference. The study successfully evaluated safety, tolerability, and pharmacokinetics of CK-586, a drug being developed for potential treatment in specific cardiac patients.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing